Pharmacokinetics and Pharmacodynamics of Oral Transmucosal Dexmedetomidine.

• Status: Completed
• Trial end date: 2019-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

Oral trans-mucosal administration is relatively easy and convenient, it also reduces first pass metabolism and has been used successfully for fentanyl, ketamine, and midazolam premedication.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• ASA physical status I - II.

• Aged between 20 and 60 years.

• Scheduled for modified radical mastectomy

Exclusion Criteria:

• Cardiac disease.

• Hepatic disease.

• Renal disease.

• History of alcohol or drug abuse.

• Patients with a known allergy to the study drug